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Abstract
Introduction PolycombGroup (PcG) proteins maintain gene
repression through histone modifications and have been
implicated in stem cell regulation and cancer. EZH2 is part of
Polycomb Repressive Complex 2 (PRC2) and trimethylates
H3K27. This histone mark recruits the BMI1-containing PRC1
that silences the genes marked by PRC2. Based on their role in
stem cells, EZH2 and BMI1 have been predicted to contribute
to a poor outcome for cancer patients.
Methods We have analysed the expression of EZH2 and BMI1
in a well-characterised dataset of 295 human breast cancer
samples.
Results Interestingly, although EZH2 overexpression correlates
with a poor prognosis in breast cancer, BMI1 overexpression
correlates with a good outcome. Although this may reflect
transformation of different cell types, we also observed a
functional difference. The PcG-target genes INK4A and ARF are
not expressed in tumours with high BMI1, but they are
expressed in tumours with EZH2 overexpression. ARF
expression results in tumour protein P53 (TP53) activation, and
we found a significantly higher proportion of TP53 mutations in
tumours with high EZH2. This may explain why tumours with
high EZH2 respond poorly to therapy, in contrast to tumours
with high BMI1.
Conclusions Overall, our data highlight that whereas EZH2 and
BMI1 may function in a 'linear' pathway in normal development,
their overexpression has different functional consequences for
breast tumourigenesis.
Introduction
PolycombGroup (PcG) proteins are transcriptional repressors
that contribute to the maintenance of cellular identity. Interest-
ingly, several members of the PcG family have been implicated
in stem cell regulation and malignancy, including breast can-
cer [1]. PcG proteins function in distinct multi-protein com-
plexes, which can be roughly distinguished into a silencing
initiation complex (Polycomb Repressive Complex 2 (PRC2))
ARF/Arf: CDKN2A/cdkn2a (cyclin-dependent kinase inhibitor 2A), Alternative Reading Frame, a.k.a. p14/p19; ATM/ATR pathway: ataxia telangiecta-
sia- and Rad 3 related pathway; BMI1/Bmi1: B-cell-specific Moloney murine leukemia virus integration site 1; CDKN2A/Cdkn2a: cyclin-dependent 
kinase inhibitor 2A; CI: confidence interval; CISH: chromogenic in situ hybridisation; cRNA: complementary RNA; c-Myc: myelocytomatosis onco-
gene; EED/Eed: embryonic ectoderm development; ER: oestrogen receptor; EZH2/EZH2: enhancer of zeste homologue 2; H3K27: lysine 27 in his-
tone H3; H3K27me3: trimethylation of lysine 27 in histon H3; HER2: Human Epidermal growth factor Receptor 2; HR: Hazard Ratio; IHC: 
immunohistochemistry; INK4a/Ink4a: CDKN2A/cdkn2a (cyclin-dependent kinase inhibitor 2A), a.k.a. p16, RING1B/Ring1b = RNF2 = ring finger pro-
tein 2; OR: odds ratio; PcG: polycomb group; PRC: polycomb repressive complex; Rb: retinoblastoma; SUZ12/Suz12: suppressor of zeste 12 
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and a complex involved in maintenance of gene silencing
(PRC1). The core members of PRC2 are EZH2, SUZ12 and
EED. The PRC1 complex, which exhibits a more variable com-
position, includes BMI1 and RING1b [2]. PRC2-member
EZH2 catalyses the histone mark characteristic for PcG-medi-
ated silencing: trimethylation of lysine 27 in histone H3
(H3K27me3) [3]. This mark is required for the recruitment of
the PRC1 complex [4,5].
BMI1 is a crucial member of the PRC1 complex and deter-
mines the extent of repression of PcG target genes [6-8]. For
instance, wildtype BMI1 levels prevent premature expression
of the INK4a/Arf locus [5,9]. This region encodes two tumour
suppressor genes, p16INK4a and p14Arf, that are normally not
expressed. When oncogene activation, such as overexpres-
sion of c-Myc, occurs a tumour-protective response is trig-
gered in the cell, causing expression of INK4a and ARF. INK4a
expression results in activation of the retinoblastoma protein
(Rb) that induces cell cycle arrest, whereas ARF expression
results in stabilisation of tumour protein P53 (TP53) that can
cause either cell cycle arrest or apoptosis [10,11]. However,
overexpression of BMI1 can keep the tumour suppressive
INK4a/ARF locus silenced, even in the presence of oncogenic
signaling, providing an explanation for the collaboration
between BMI1 and c-Myc in tumourigenesis [7].
In Bmi1-knockout mice, Ink4a and Arf are expressed at an
early age, resulting in premature senescence and progressive
loss of adult stem cells [1,12]. Bmi1 was shown to be required
for the maintenance of haematopoietic and neural stem cells,
through repression of the Ink4a/Arf locus and other PcG tar-
get genes [12-14]. We recently showed that loss of Bmi1
reduces stem cell activity in the mammary gland as well,
although Bmi1 is also required for the proliferation of more
committed cells [6]. The role of Bmi1 in adult stem cells, com-
bined with its frequent overexpression in cancer, has led to the
theory that BMI1 might play a role in cancer stem cells (or
more accurately, tumour-initiating cells) [15,16]. These cells
are thought to be more resistant to therapy [17-19] and a
BMI1 overexpression signature has subsequently been corre-
lated with poor prognosis in several tumour types, including
breast cancer [15]. However, more recent reports suggest
that BMI1 overexpression is associated with a good outcome
in breast cancer [1,2].
In contrast, the link between EZH2 overexpression and
reduced breast cancer survival is well established. EZH2 over-
expression correlates with late stage disease [3,4] and can
even be an independent predictor of aggressive breast cancer
[5,6]. A causal link between EZH2 overexpression and a
malignant phenotype was observed in human papillomavirus-
transformed human mammary epithelial cells where EZH2
overexpression conferred anchorage-independent growth and
invasive properties to these cells [3]. In mouse development,
deletion of EZH2 is embryonic lethal. EZH2 was shown to be
required for embryonic stem cells [7], and although less is
known about EZH2 function in adult stem cells, it does play a
role in haematopoietic stem cells [8]. In the mammary gland,
EZH2 expression is coupled with proliferation, but in tumours
EZH2 expression is also found in resting cells [4].
In light of the potential role of PcG proteins in cancer stem
cells [9,10], we investigated the controversial role of BMI1 in
breast cancer and compared it with EZH2 to obtain more of an
insight into polycomb function in tumourigenesis. We found
that in contrast to EZH2, BMI1 overexpression correlates with
a good prognosis. Moreover, we found inverse correlations for
BMI1 and EZH2 expression with several clinical characteris-
tics, as well as different tumour subtypes. Finally, we identified
a possible mechanism to explain why BMI1 overexpression
may contribute to a better outcome than EZH2 overexpression
in breast cancer.
Materials and methods
Tumour samples and patient characteristics
We have previously published the gene expression profiles of
tumours from 295 stage 1 and stage 2 breast cancer patients
treated at the Netherlands Cancer Institute between 1984 and
1995 [11]. Data on overall survival was available for all
patients [11] and clinical information was last updated on 1
January 2005. The median follow up is 10.2 years for all
patients and 12 years for patients who are alive. One hundred
and sixty-five patients received local therapy, 20 received
tamoxifen only, 20 received tamoxifen plus chemotherapy and
90 received chemotherapy.
Classification of tumour samples according to gene 
expression
Expression data was obtained from 25,000 oligo arrays com-
paring complementary RNA (cRNA) from individual tumour
samples with a pool containing equal amounts of cRNA from
all patients [12,13]. For categorisation into high and low
expression groups for EZH2 [GenBank:NM004456], BMI1
[GenBank:NM005180], EED [GenBank:AF099032] and
RING1B [RNF2, GenBank:NM007212], we chose a log2
ratio of 0 as the cut-off point, which resulted in 40%, 38%,
44% and 52% of patients having high levels of expression,
respectively.
Classification of intrinsic molecular subtypes was carried out
according to new guidelines [14]. Patients were furthermore
categorised based on the 70-gene signature [12], death-from-
cancer signature [15] and Genomic Health Score [16].
Statistical analysis
Time-to-event data were illustrated by Kaplan-Meier plots and
groups were compared using the Cox-Mantel log-rank test.
Overall survival was defined as the time from age at diagnosis
to age at death or end of follow up, whichever occurred first.
Cox proportional hazards regression analyses were used toAvailable online http://breast-cancer-research.com/content/10/6/R109
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calculate uni- and multivariate hazard ratios (HR) and their
95% confidence intervals (CI). Multivariate HRs were adjusted
for tumour grade, nodal status and tumour diameter. Associa-
tions between categorical variables were evaluated by Pear-
son's chi-squared test or by logistic regression. Statistical
significance was assessed at the two-sided 5% level. All sta-
tistical analysis was done using SAS 9.1 (SAS Institute Inc.,
Cary, NC, USA).
Immunohistochemistry
For all breast carcinomas, BMI1, EZH2, oestrogen receptor
(ER), human epidermal growth factor receptor (HER) 2 and
TP53 status were assessed by immunohistochemistry on tis-
sue microarrays using a manual tissue arrayer (Beecher Instru-
ments, Inc, Sun Prairie, WI, USA). From each individual
paraffin-embedded tumour, 600 m core tissue biopsies were
taken and arrayed in triplicate in a new paraffin block. Serial
sections of 3 m were cut from the tissue microarray blocks,
deparaffinised in xylene and hydrated in a graded series of
alcohol. After antigen retrieval in citrate buffer, staining was
performed using the Lab Vision Immunohistochemical Auto-
stainer (Lab Vision Products
Thermo Fisher Scientific, Fremont, CA, USA) with primary anti-
bodies against ER-alpha (1D5+6F11, dilution 1:50, Neomark-
ers (Lab Vision Products
Thermo Fisher Scientific, Fremont, CA, USA)), HER2 (3B5,
dilution 1:3000), TP53 (DO-7, dilution 1:6000), EZH2 (AE25,
dilution 1:10, gift from Kristian Helin) and BMI1 (F6, dilution
1:400, Millipore). ER-staining was scored as positive when
more than 10% of tumour cells showed staining, and TP53
staining was considered positive when more than 50% of
tumour cells showed staining. A tumour was considered
HER2 positive with a score of 3+ and negative with a score of
0, according to common pathological guidelines. Tumours
with a score of 2+ were evaluated by chromogenic in situ
hybridisation (CISH) and scored positive when HER2 gene
amplification was found.
TP53 mutation analysis
When RNA was isolated from tumour tissue using TRIzol rea-
gent (Invitrogen, Breda, Netherlands), the DNA fraction was
used for TP53 mutation analysis. TP53 mutation detection in
tumour DNA was performed by sequencing exon 2 to 11 using
the 3730 DNA analyser (Applied Biosystems Inc, Foster City,
CA, USA). All fragments were sequenced in both directions
and the primers used were linked to universal M13 sequences.
PCR products were purified with MultiScreen PCR96 Plate
(Millipore) on epMotion™5075 (Eppendorf, Westbury, NY,
USA). In a 20 l PCR reaction, 50 ng DNA was amplified using
HotStarTaq DNA Polymerase (Qiagen, Valencia, CA, USA)
and touchdown PCR with annealing temperatures from 68°C
to 56°C. BigDye Terminator reaction mix v1.1 was used in the
sequencing reacion, and the products were purified with
Sephadex G-50 Superfine. SeqScape software v2.5 (Applied
Biosystems Inc, Foster City, CA, USA) was used for alignment
to reference sequence and the scoring were carried out by
two experienced operators independently. GeneBank acces-
sion number [Genbank:NM000546] was used as a reference
sequence.
Results
Inverse correlation of PRC1 and PRC2 members with 
survival
We evaluated the association between BMI1 or EZH2 expres-
sion and overall survival among 295 breast cancer patients
[11,12]. For each gene, we divided patients into a high and
low expression group as determined by microarray analysis.
Univariate survival analysis corroborated previous data [3,5]
that patients with high EZH2 expression have a shorter overall
survival than patients with low EZH2 (Figure 1a). In contrast,
patients with high expression of BMI1 showed increased over-
all survival. Two other PcG members that showed an effect on
overall survival are EED and RING1B (RNF2). Interestingly,
high expression of EED, which like EZH2 is a PRC2 member,
is also associated with a shorter survival time whereas high
expression of RING1B, the binding partner for BMI1, is corre-
lated with a favourable disease outcome. Similar associations
were found when the mRNA expression was regarded as a
continuous variable (Figure 1b). However, after adjustment for
clinical characteristics, only EZH2 and BMI1 remain signifi-
cantly associated with survival time, albeit in opposite direc-
tions. The HR for EZH2 is not affected by the lymph node
status of the patients, but the 'protective' effect of BMI1
expression is limited to lymph node-positive patients (Figure
1c).
The differential association with survival suggests that EZH2
and BMI1 are not overexpressed in the same tumours. As illus-
trated in Figure 1d, there is indeed a negative correlation
between EZH2 and BMI1 expression. Although there does not
seem to be absolute incompatibility between high levels of
BMI1 and EZH2, tumours with high BMI1 have only about half
the chance to have high EZH2 compared with tumours with
low BMI1 (odds ratio (OR) = 0.55, p = 0.0166). Of note,
tumours with both high EZH2 and BMI1 expression have a HR
of 0.6 (95% CI = 0.3 to 1.2) compared with tumours that have
high EZH2 and low BMI1, suggesting that the favourable
effect of BMI1 overexpression is dominant over the adverse
effects of EZH2.
BMI1 correlates with favourable tumour characteristics
To obtain further insight into the differential associations of
BMI1 and EZH2 with overall survival, we analysed the mRNA
expression levels of these PcG genes in tumours ranked
according to grade (Figure 2a). Grade 3 tumours, which have
a worse prognosis than grade 1 and 2 tumours, expressed sig-
nificantly more EZH2 and less BMI1 than tumours of lowerBreast Cancer Research    Vol 10 No 6    Pietersen et al.
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Figure 1
EZH2 and BMI1 are inversely correlated EZH2 and BMI1 are inversely correlated. (a). Univariate survival analyses by Kaplan-Meier plots and log rank tests. Patients were categorised by 
high or low expression of the different Polycomb group (PcG) members based on microarray data. (b) Relative risk of death evaluated by Cox regres-
sion modelling and continous PcG mRNA levels. Multivariate analysis is adjusted for tumour size, lymph node (LN) status and grade. (c) Relative risk 
of death based on continous EZH2 and BMI1 levels in LN-positive and LN-negative patients. P het = p value indicating heterogeneity of BMI1 levels 
across LN-positive and LN-negative patients. (d) Two-by-two table for categorical EZH2 and BMI1 levels. Odds ratio (OR) = 0.55 (95% confidence 
interval (CI) = 0.33 to 0.90) for high EZH2 among patients with high BMI1 compared with low BMI1 (chi-squared: p = 0.017).Available online http://breast-cancer-research.com/content/10/6/R109
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grade (Kruskal-Wallis test, p = 0.001). Although we observed
an effect of BMI1 in lymph node-positive patients only, there is
no significant variation in the expression levels of BMI1 or
EZH2 according to lymph node status or age at diagnosis
(data not shown). Next, we tested whether PcGs are associ-
ated with ER status. High BMI1 expression comes with a sig-
nificantly higher frequency of ER-positive tumours (Wilcoxon
test p < 0.001), which seems to be mainly due to a lack of
BMI1 expression in ER-negative tumours (Figure 2b). In con-
trast, high EZH2 expression is negatively correlated with ER
expression (Wilcoxon test p < 0.001).
EZH2 is one of a set of 70 genes whose expression predicts
a poor outcome in breast cancer [12], so it is not surprising
that most patients with high EZH2 exhibit this poor prognosis
signature. Conversely, patients with a poor 70-gene profile are
overrepresented in the category with low BMI1 expression,
consistent with our observations that low BMI1 expression is
associated with decreased overall survival (Figure 2c).
EZH2 has been linked to proliferation in several tumour types
[5,6]. We also find a positive correlation between EZH2 and
proliferation (Pearson correlation 0.61) in our dataset when
Figure 2
EZH2 and BMI1 inversely correlate with variables associated with survival EZH2 and BMI1 inversely correlate with variables associated with survival. (a) EZH2 and BMI1 distribution differ by grade. Mean EZH2 mRNA 
levels are -0.62 (n = 75), -0.21 (n = 101) and 0.37 (n = 119) for grades 1, 2 and 3, respectively (p < 0.0001 Kruskal-Wallis test). Mean BMI1 mRNA 
levels are 0.0067, -0.15 and -0.41 for grades 1, 2 and 3, respectively (p = 0.0001 Kruskal-Wallis test). (b) EZH2 and BMI1 distribution differ by oes-
trogen receptor (ER) status. Tumours are regarded ER-positive when more than 10% of the tumour cells stain positive for ER immunohistochemistry 
and ER-negative otherwise. Mean EZH2 levels are 0.34 for ER-negative (n = 81) tumours and -0.27 for ER-positive (n = 214) tumours (p < 0.0001 
Wilcoxon test). Mean BMI1 levels are -0.56 for ER-negative and -0.08 for ER-positive tumours (p < 0.0001 Wilcoxon test). (c) EZH2 and BMI1 dis-
tribution differ by 70-gene profile. Mean EZH2 levels are -0.58 for tumours with a good prognosis signature (n = 115) and 0.22 for tumours with a 
poor prognosis signature (n = 180) (p < 0.0001 Wilcoxon test). Mean BMI1 levels are -0.005 for good prognosis tumours and -0.35 for poor prog-
nosis tumours (p < 0.0001 Wilcoxon test).Breast Cancer Research    Vol 10 No 6    Pietersen et al.
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using the five genes from the Genomic Health Score [16] to
reflect the proliferation status of the tumours. Conversely,
BMI1 expression is negatively correlated (-0.27) with tumour
cell proliferation.
An 11-gene signature, based on a mouse model of metastatic
prostate cancer and on BMI1-deficient versus BMI1-proficient
neurospheres, has been suggested to reflect BMI1-regulated
'stem cell-ness' pathways and to predict a poor outcome in
breast cancer [15]. In our analysis, however, this 11-gene sig-
nature showed a negative correlation with BMI1 expression
(Pearson correlation coefficient -0.24) and a positive correla-
tion with EZH2 expression (correlation coefficient 0.47), sug-
gesting that this signature does not reflect BMI1 function.
Overall, tumours with high BMI1 expression display character-
istics of less malignant tumours and are correlated with
increased survival.
High BMI1 expression is restricted to luminal breast 
cancer subtypes
Breast cancer is a heterogeneous disease and tumours are
classified into distinct subgroups based on morphology or
gene expression profiles. The molecular subtypes identified by
Perou and colleagues [17] and Sørlie and colleagues [18]
showed a striking difference in survival. Furthermore, it has
been postulated that the differences between breast cancer
subgroups may be due to the fact that they derive from differ-
ent cells of origin [19,20]. For instance, the basal subtype
expression profile harbors characteristics of undifferentiated
cells, whereas the luminal A subtype expresses genes indica-
tive of luminal epithelial cells such as mucin and ER. It is pos-
sible that these distinct tumours arise from the oncogenic
transformation of a mammary stem cell or a more committed
luminal progenitor, respectively. This idea fits with a recent
publication that demonstrated that the cell type, or epigenetic
make-up, determines for a large part the phenotype and malig-
nancy of the resulting tumour [21].
Therefore, we explored whether EZH2 or BMI1 expression
was associated with a specific molecular subtype. When
ranked according to prognosis, the basal subtype has the
worst prognosis, followed by the Erb-B2+, normal-like and
luminal B tumours. The luminal A subtype has by far the best
prognosis [14,18]. We found a substantial heterogeneity of
EZH2 and BMI1 levels across the subtypes (p < 0.0001, Fig-
ure 3a). Analysis of the distribution of the distinct molecular
subtypes in patients with either high or low BMI1 expression
demonstrates that whereas all subtypes are represented in the
BMI1-low group, the BMI1-high group consists mainly of the
luminal subtypes, particularly luminal A (Figure 3b). This is con-
sistent with the association of BMI1 with ER-positive tumours
as luminal A tumours are usually ER-positive and luminal B
tumours generally show a lower ER-expression than luminal A
[18]. For EZH2, we find an under-representation of the normal-
like subtype in tumours with high EZH2-expression, and an
overrepresentation of luminal A type tumours in the group with
low EZH2 expression (Figure 3b).
The heterogeneity of the different breast cancer subtypes with
respect to overall survival, and the possibility that tumours of
different subtypes may derive from different cells of origin, sug-
gest that the expression levels of EZH2 and BMI1 in breast
tumours reflect a pre-existing expression pattern in different
cell types within the mammary gland. Therefore, we stained
normal mammary gland tissue as well as breast tumour mate-
rial for both BMI1 and EZH2 protein expression. BMI1 was
expressed in virtually all cells of the mammary gland, but par-
ticularly high in luminal cells (Figure 3c), similar to what we
observed in mouse mammary tissue [22]. EZH2 expression
seems to be low in general (Figure 3c) and is possibly
restricted to proliferating cells only, as reported previously [4].
Alternatively, EZH2 expression may be restricted to a less
abundant cell population such as, for instance, stem cells.
We have performed immunohistochemistry (IHC) on a tissue
microarray from the same 295 patients that were used for the
microarray-based analyses. However, correlation of the cate-
gorical BMI1 IHC groups with the continuous mRNA variable
is low, although the correlation for EZH2 is somewhat better.
Careful analysis by an experienced pathologist (MJV) indi-
cated that the BMI1 IHC signal is high in most cells and there
is a limited range of BMI1 expression, precluding a reliable cat-
egorisation of the samples based on IHC. A higher variation of
EZH2 staining intensity between samples partially overcomes
this problem. Nevertheless, we found that both BMI1 and
EZH2 epitopes are particularly sensitive to the age of the tis-
sue, as well as the time between sectioning and staining. Con-
sequently, even though the staining pattern within one patient
sample is informative, we have based our comparison of the
different tumour samples on the more quantitative mRNA
expression data.
Low frequency of TP53 mutations in tumours with high 
BMI1 expression
Although the inverse correlation of EZH2 and BMI1 with sur-
vival may simply reflect the transformation of different cell
types, this differential association may also be explained by a
functional difference between both Polycomb genes. The
INK4a/ARF locus is a known target of polycomb repression,
so we analysed expression of this locus in relation to BMI1 and
EZH2. As expected, we did not find high INK4a/ARF expres-
sion in tumours with high BMI1 mRNA expression (Figure 4a).
However, to our surprise, tumours with high EZH2 expression
did have high INK4a/ARF expression in 33% of the cases. This
suggests that while overexpression of BMI1 is capable of
blocking oncogene-induced INK4a/ARF expression, this is not
the case for EZH2 overexpression. A consequence of ARF
induction is stabilisation of TP53 [23], resulting in apoptosis or
cell cycle arrest. Thus, cells expressing high EZH2 levelsAvailable online http://breast-cancer-research.com/content/10/6/R109
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Figure 3
Correlation of EZH2 and BMI1 expression with molecular subtypes Correlation of EZH2 and BMI1 expression with molecular subtypes. (a) Mean mRNA levels of EZH2 and BMI1 in the different subgroups. The 
distribution of both EZH2 and BMI1 over the subgroups differ significantly, Kruskall-Wallis test. (b) Distribution of subgroups over categorised EZH2 
and BMI1 levels. (c) Immunohistochemistry on EZH2 and BMI1 in normal breast tissue, an ErbB2-type and a luminal A-type tumour. Pictures were 
taken at 40× magnification (left panels) and a zoomed-in section is shown on the right of each image.Breast Cancer Research    Vol 10 No 6    Pietersen et al.
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would come under selection for mutations in TP53 once they
progress to malignancy [24]. In contrast, there would be no
selection pressure towards mutant TP53 in tumours in which
high BMI1 levels block INK4a/ARF expression induced by
oncogenic stress.
To test this hypothesis, we analysed TP53 status in our patient
data set. Positive TP53 staining as detected by IHC is fre-
quently used as an indicator of mutated TP53 [25]. However,
because not all mutations result in increased expression, we
also used TP53-mutation status based on sequencing (for
204 of the 295 patients). Consistent with the increased ARF
expression, we observed more tumours with a strong TP53
staining or a mutant TP53 sequence in the EZH2-high group
(Figure 4b). In contrast, tumours with high BMI1 are five times
less likely to have mutated TP53 (Figure 4c). To further sub-
stantiate this observation, we made use of a gene expression
signature that was found to reflect TP53 status in breast can-
cer [26]. Again, we found significantly more tumours with a
mutant TP53 signature when EZH2 expression is high [see
Additional data file 1].
Discussion
BMI1 has been proposed to play a role in cancer stem cells or
tumour-initiating cells [10,27] because of its function in normal
stem cells and its role as an oncogene. It has been postulated
that cancer stem cells are particularly resistant to therapy [28],
so high levels of BMI1 would be expected to be associated
Figure 4
Differential effect of BMI1 and EZH2 on INK4a/ARF locus and association with TP53 mutations Differential effect of BMI1 and EZH2 on INK4a/ARF locus and association with TP53 mutations. (a) Dotplot of INK4a/ARF (CDKN2A) expres-
sion versus BMI1 and EZH2 expression. INK4a/ARF expression is not found in tumours with high BMI1 mRNA, whereas it does occur in tumours 
with high EZH2 (red circle). (b) Distribution of patients with positive TP53 staining (mutated TP53) differs by categorised EZH2 and BMI1 levels. 
TP53 immunohistochemistry (IHC) data was obtained from 273 patients and the TP53 sequence was analysed in 204 tumours. The distribution of 
mutant TP53 shows a similar pattern (TP53 mutation). (c) Logistic regression analysis of TP53 IHC and sequence status on EZH2 and BMI1 levels. 
CI = confidence interval, OR = odds ratio.Available online http://breast-cancer-research.com/content/10/6/R109
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with a poor prognosis. In several tumour types, such as leukae-
mia and hepatocellular carcinoma, BMI1 overexpression is
indeed correlated with reduced survival [29,30]. However, our
data demonstrated that in breast cancer this is not the case. In
fact increased BMI1 expression is associated with a good
prognosis. Two recent reports also documented the associa-
tion of BMI1 expression with survival after breast cancer. In
both datasets BMI1 expression is associated with ER-positive
disease, and in one set BMI1 is an independent predictor of
good prognosis [1,2]. These studies used IHC and show a
reasonable correlation with mRNA expression, indicating that
although the range of BMI1 protein detection may be limited,
both mRNA and protein levels give a similar result regarding an
association of BMI1 with a positive outcome.
We further show that high BMI1 expression is limited to the
luminal breast cancer subtypes, and is inversely correlated
with PcG members from the silencing initiation complex,
PRC2. There could be several, not mutually exclusive, reasons
for the differential association of EZH2 or BMI1 overexpres-
sion with overall survival. First, high BMI1 or EZH2 levels may
reflect a different cell of origin for the respective tumours. Ince
and colleagues recently demonstrated that the introduction of
identical transforming mutations in different mammary epithe-
lial cell types resulted in strikingly different oncogenic potential
of these cells [21]. This implies that the pre-existing expression
patterns or differentiation state of a cell determines how malig-
nant that cell can become. Because we found different expres-
sion patterns for EZH2 and BMI1 in the normal mammary
gland, it is possible that the expression levels we detected in
the tumours are a reflection of BMI1 and EZH2 expression in
the cell of origin. The fact that EZH2 is expressed in a small
subset of cells in the mammary gland, is found overexpressed
in the undifferentiated basal subtype and is associated with a
poor prognosis suggests that EZH2 might play a role in mam-
mary stem cells. Nevertheless, EZH2 expression is not limited
to a particular subtype and is also linked to the proliferative
state of cells: therefore, a possible link between EZH2 and
mammary stem cells remains to be demonstrated. Importantly,
we find little evidence for a role of BMI1 in the transformation
of mammary stem cells. Both in the human and the mouse
mammary gland, BMI1/Bmi1 is expressed in all cells, but is
particularly high in luminal cells. In the mouse, we observed
that loss of Bmi1 reduces mammary stem cell activity, but
Bmi1 is also required for the proliferation of more committed
cells [22]. In addition, we found that high BMI1 levels are
mainly restricted to ER-positive luminal A type tumours. Fur-
thermore, Shipitsin and colleagues did not find an increase in
BMI1 in the tumour-intiating population [31]. Therefore, a role
for BMI1 in the transformation of luminal progenitors or even
more committed luminal epithelial cells is more likely. The dif-
ferentiation state of these cells may contribute to a less
aggressive phenotype after transformation.
Although BMI1 expression does not seem to be restricted to
ER-positive cells in normal mammary gland tissue, we found a
strong correlation between BMI1 overexpression and positive
ER status in the human breast cancer samples. It is possible
that ER-positive cells derive a selective advantage from BMI1
overexpression. In the normal mammary gland, ER-positive
cells are growth arrested. They sense the growth signal from
oestrogen levels, but pass this on via paracrine factors that
induce growth in neighbouring ER-negative cells [32,33]. This
could be viewed as a tumour-protective strategy and the
growth arrest is indeed abrogated in ER-positive tumours,
which have become dependent on oestrogen for their prolifer-
ation [34,35]. A recent study showed that whereas normal ER-
positive cells are rapidly lost in cell culture because of their
growth arrest, BMI1 overexpression allows proliferation of
cells expressing the ER [36]. It will be interesting to determine
if this is due to the repression of the INK4a/ARF locus or if
other BMI1-target genes are involved. The strong association
of BMI1 overexpression and luminal A type tumours may there-
fore suggest that BMI1 is selectively oncogenic in ER-positive
cells, where it can over-rule their arrested state.
In contrast to BMI1, we found that EZH2 overexpression is
negatively correlated with ER expression. In two cell culture
systems, EZH2 overexpression was shown to repress and
activate ER signaling, respectively [37,38]. However, most
ER-positive tumours have low EZH2 and the reported core-
pressor for EZH2 is downregulated in high-grade tumours,
where EZH2 expression is high. Hence, it seems unlikely that
involvement of EZH2 in ER-signaling contributes greatly to an
oncogenic role of EZH2 in breast cancer.
EZH2 may, however, be involved in oncogenic transformation
by attenuating DNA repair, thereby increasing genomic insta-
bility [39]. Whereas this could contribute to tumourigenesis by
increasing the mutation rate, it was also shown to make cells
in culture more sensitive to radiation or etoposide [39]. How-
ever, EZH2 was introduced into cell lines with functional
TP53, which could explain the increased sensitivity to therapy.
Importantly, our data show that primary tumours with EZH2
overexpression frequently overexpress INK4a/ARF and harbor
TP53 mutations. Even though ectopic EZH2 may sensitise
cells with wildtype TP53 to treatment, our data suggest that
during tumourigenesis EZH2 overexpression coincides with
TP53 activation, either through genomic instability or ARF
induction. Therefore the resulting tumours would derive from
clones that have accrued TP53 mutations, rendering them
more resistant to therapy, as indicated by the link of EZH2 with
poor overall survival.
Apparently, EZH2 overexpression is not capable of repressing
the INK4a/ARF locus in the presence of oncogenic signaling,
unlike BMI1 overexpression. Indeed, in human fibroblasts
ectopic EZH2 is not recruited to the INK4a/ARF locus, in con-
trast to ectopic BMI1 [40]. BMI1 levels determine the extent ofBreast Cancer Research    Vol 10 No 6    Pietersen et al.
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repression of its target genes [41], so we propose the follow-
ing model with regard to the differential roles of BMI1 and
EZH2 in breast tumourigenesis (Figure 5). Overexpression of
BMI1 results in increased silencing of PcG target genes such
as the INK4a/ARF locus. Whereas wildtype levels of BMI1
would not be sufficient to prevent activation of INK4a/ARF by,
for instance, oncogenic stress, overexpression of BMI1 can
block this activation and thus prevent TP53 activation. In that
case, there is no selection pressure towards mutant TP53 in
BMI1 overexpressing cells. Importantly, activation of TP53 by
DNA damage occurs via ATM/ATR signaling and not via ARF
[42,43], which implies that treatment of BMI1-expressing
tumours with DNA damaging drugs should activate the TP53
pathway to induce apoptosis. It has been shown that TP53
status can indeed predict response to therapy in breast can-
cer [44]. Interestingly, the protective effect of BMI1 is not
observed in lymph node-negative patients, who undergo
resection and local treatment only (Figure 1c). In contrast,
BMI1 overexpression associates with a good prognosis for
lymph node-positive patients, who receive chemotherapy, hor-
mone therapy or both. Finally, the observation that BMI1 over-
expression still confers a protective effect in tumours with high
EZH2 supports this model in which BMI1 overexpression pre-
vents TP53 mutations and thus results in a better response to
therapy.
For EZH2 on the other hand, our data imply that overexpres-
sion of this PcG member can not prevent the activation of the
INK4a/ARF locus. We suggest that the selection for TP53
mutations contributes to the poor outcome observed in
tumours with high EZH2, but not BMI1, expression.
Possibly, the main molecular function of EZH2 is in 'tagging'
which genes need to be silenced rather than silencing the
Figure 5
Model for the different oncogenic roles of EZH2 and BMI1 Model for the different oncogenic roles of EZH2 and BMI1. (a) In normal development, genes such as the INK4a/ARF locus are bound by EZH2, 
marked by H3K27me3 and bound by BMI1. (b) On oncogene activation (indicated by lightning symbol) such as constitutive Ras or Myc expression, 
the INK4a/ARF locus becomes expressed as part of a tumour suppressive response. (c) Increased BMI1 expression results in more BMI1 protein 
binding to known Polycomb group (PcG)-target genes. This prevents activation of these genes even when signals are present that would normally 
activate these genes. (d) Increased EZH2 expression does not prevent INK4a/ARF activation (although this locus may still be inactivated by other 
mechanisms). In contrast, the role of EZH2 in tumourigenesis may be due to silencing of genes not normally targeted by PcG or due to methylation 
of non-histone proteins (indicated by diamond on protein 'X').Available online http://breast-cancer-research.com/content/10/6/R109
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genes itself. Arguably, the INK4a/ARF locus is already satu-
rated by H3K27me3 and increased EZH2 levels do not affect
this, whereas an increase in BMI1 levels results in more BMI1
being present at the locus [40]. By nature of its catalytic activ-
ity, overexpression of EZH2 could result in the silencing of
genes that are normally not PcG targets, as also suggested by
Tan and colleagues [45]. This group identified a set of tumour-
specific PcG target genes and validated this in primary human
breast tumour samples. We could not find a correlation
between reduced expression of these genes and high EZH2
expression in our data set (data not shown). It is conceivable
that EZH2 is not specifically recruited to new targets, but
silences genes at random. Those genes whose silencing con-
tributes to an oncogenic phenotype would subsequently be
selected during tumourigenesis. Depending on accompanying
mutations, different genes are likely to be selected for silenc-
ing in different tumours, making it difficult to detect a specific
epigenetic profile for EZH2 overexpression. Nevertheless, it is
likely that EZH2 has an INK4a/ARF-independent function in
cancer, because in mammary epithelial cells in which Rb and
TP53 had been inactivated, ectopic expression of EZH2 con-
tributed to anchorage-independent growth and invasion [3].
Interestingly, EZH2 was found to methylate cytoplasmic pro-
teins involved in Akt-signaling [46], suggesting that the onco-
genic role of EZH2 in breast cancer could also be unrelated to
its role in epigenetic regulation.
Conclusion
Overall, our data indicate that important functional differences
exist between different PcG proteins. Specifically, although
under normal circumstances EZH2 and BMI1 work in a 'linear'
pathway, that is, BMI1 recruitment to a target gene depending
on the H3K27me3 mark set by EZH2, the overexpression of
these genes seems to have very different consequences with
regard to, for instance, INK4a/ARF expression and TP53
mutations. Future studies on the causal involvement of PcG
proteins in stem cell regulation and tumourigenesis should
take into account the molecular function of individual poly-
comb members as well as potential differences in cells of ori-
gin.
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